Olean Times Herald

Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Appl...

Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Appl...

NEW YORK , March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today an...

NEW YORK , March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. ( NASDAQ: HOTH ), a biopharmaceutical company focused on developing first-in-class t...

New Data Demonstrates Significant Reduction in Tumor Growth and KITExpression in Preclinical GIST Models NEW YORK , March 18, 2025 /PRNewswire/ -- Hot...

HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (...

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting , which takes place March 7-11, 2025 , highlighting HT-001...

Key Findings from the Study: NEW YORK , March 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH),a clinical-stage biopharmaceutical compan...

NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, t...